These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37160267)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.
    Saeed DK; Shakoor S; Razzak SA; Hasan Z; Sabzwari SF; Azizullah Z; Kanji A; Nasir A; Shafiq S; Ghanchi NK; Hasan R
    BMC Microbiol; 2022 Feb; 22(1):62. PubMed ID: 35209842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of bedaquiline drug-susceptibility testing by BACTEC MGIT 960 system for
    Sivaramakrishnan G; Subramanyam B; Kumar MP; Golla R; Tripathy SP; Mondal R
    Int J Mycobacteriol; 2019; 8(4):329-332. PubMed ID: 31793501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678.
    Snobre J; Villellas MC; Coeck N; Mulders W; Tzfadia O; de Jong BC; Andries K; Rigouts L
    Sci Rep; 2023 Jun; 13(1):10444. PubMed ID: 37369740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
    Blankson HNA; Kamara RF; Barilar I; Andres S; Conteh OS; Dallenga T; Foray L; Maurer F; Kranzer K; Utpatel C; Niemann S
    Microbiol Spectr; 2024 Mar; 12(3):e0240523. PubMed ID: 38289066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.
    Madadi-Goli N; Ahmadi K; Kamakoli MK; Azizi M; Khanipour S; Dizaji SP; Nasehi M; Siadat SD; Fateh A; Vaziri F
    Ann Clin Microbiol Antimicrob; 2024 Apr; 23(1):36. PubMed ID: 38664815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
    Divita KM; Khatik GL
    Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sub-MIC levels of bedaquiline and clofazimine can select
    Villellas C; Stevenaert F; Remmerie B; Andries K
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation.
    Swain SS; Pati S; Hussain T
    Eur J Med Chem; 2022 Mar; 232():114173. PubMed ID: 35168150
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Setyawan MF; Mertaniasih NM; Soedarsono S; Nuha Z; Maladan Y; Matsumoto S
    Int J Mycobacteriol; 2023; 12(2):122-128. PubMed ID: 37338471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.
    Suman SK; Chandrasekaran N; Priya Doss CG
    Clin Microbiol Rev; 2023 Dec; 36(4):e0008823. PubMed ID: 38032192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.